Latest news and press releases about Rezolute, Inc. (RZLT): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsu...
Price
| Price | $3.98 |
| Market Cap | $383M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.27 |
| EV / EBITDA | -4.86 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -58.82% |
| Return on Invested Capital | -73.68% |
| Return on Assets | -64.95% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Explore sector: Healthcare · Biotechnology
More sections of RZLT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks